Clinical Trial

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MOA: Azenosertib inhibits WEE1, accelerating the cell cycle and driving cancer cells with genetic instability or replication stress into apoptosis

Key Eligibility Criteria:

• Histologically or cytologically diagnosed high-grade serous OC/FP/PPC
• Must have plt-resistant disease
• Primary plt-refractory excluded
• 1-3 prior lines of therapy
• Prior bevacizumab required if eligible
• Prior PARPi as maintenance required if BRCA1/2m or HRD
• Prior MIRV required if indicated
• Up to 4 prior lines of tx allowed if pt received MIRV
• Part 2 requires positive cyclin E1 protein status result determined by IHC
• Measurable disease per RECIST v1.1
• Prior therapy with any WEE1 inhibitor, ATR inhibitor, CHK1/2 inhibitor or PKMYT1 inhibitor excluded